Galen shares hit by HRT cancer scare

THE HRT cancer scare has knocked 49 cent off the Galen share price in brisk trading.

The shares fell to €8.13 as the Northern drugs group got caught up in the cancer scare findings disclosed in a major new study yesterday.

The Lancet research found that combined hormone replacement treatment containing oestrogen and progesterone caused four times as many breast cancers.